Anti-Macrophage Migration Inhibitory Factor Antibody
Metastatic Adenocarcinoma of the Colon or Rectum
Baxalta now part of Shiremonoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
67 Active assets in the Metastatic Adenocarcinoma of the Colon or Rectum cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Regorafenib City of Hope Medical Center | Phase 2 | BB |
Trifluridine Centre Hospitalier Universitaire Dijon | Phase 3 | BB |
Balstilimab City of Hope Medical Center | Phase 2 | BB |
Botensilimab City of Hope Medical Center | Phase 2 | BB |
Cetuximab Bayer | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Anti-Macrophage Migration Inhibitory Factor Antibody is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →